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Abstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance 
the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme 
that normally inactivates incretin hormones. Because of their distinct mechanism of action, 
DPP-4 inhibitors can be used as add-on therapy to other classes of drugs for treatment of type 
2 diabetes. The objective of this review is to critically evaluate clinical trials of sitagliptin and 
vildagliptin in combination with pioglitazone. The addition of either sitagliptin or vildagliptin to 
ongoing pioglitazone therapy is associated with reduction in average hemoglobin A1c (HbA1c) 
levels of approximately 0.7% compared with placebo and 1% compared with baseline after 
24 weeks. When started concomitantly in drug-naïve patients, the combination of pioglitazone 
30 mg and vildagliptin 100 mg qd reduces HbA1c by 1.9% after 24 weeks, compared with 1.1% 
with pioglitazone monotherapy. In general, the addition of DPP-4 inhibitors to pioglitazone was 
well tolerated, did not increase the incidence of hypoglycemia, and did not substantially worsen 
the weight-gain induced by pioglitazone. The combination of sitagliptpin or vildagliptin with 
pioglitazone can be a useful therapeutic approach in patients with type 2 diabetes who cannot 
tolerate metformin or a sulfonylurea.
Keywords: incretins, sitagliptin, vildagliptin, dipeptidyl peptidase inhibitors, pioglitazone, 
type 2 diabetes
Introduction
The anti-diabetic actions of the DPP-4 inhibitors are based on the two incretin hormones 
glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). Both GLP-1 
and GIP stimulate insulin secretion after meals. Moreover, GLP-1 exerts additional 
actions that target postprandial hyperglycemia: inhibition of postprandial glucagon 
secretion, delay of gastric emptying, and possible induction of early satiety (Drucker 
and Nauck 2006; Mikhail 2006). However, it was not practical to directly use GLP-1 
and GIP as pharmacological agents for treatment of diabetes because of their very 
short half-lives as result of their rapid breakdown by the enzyme DPP-4. For example, 
the half-life of GLP-1 is approximately 2 minutes after intravenous administration 
(Visboll et al 2003). To overcome this problem, inhibitors of the enzyme DPP-4 were 
used as alternatives to GLP-1 and GIP. Thus, DPP-4 inhibitors, also called incretin 
enhancers, prolong the effects of native GLP-1 and GIP and increase their serum 
levels by approximately 2-fold (Drucker and Nauck 2006). The best-studied DPP-4 
inhibitors are sitagliptin and vildagliptin. The two drugs stimulate insulin secretion 
and inhibit glucagon release after meals (Drucker and Nauck 2006; Mikhail 2006). 
They do not delay gastric emptying or induce early satiety presumably because the rise 
in GLP-1 circulating levels is not sufﬁ  ciently high to exert such effects (Drucker and 
Nauck 2006; Vella et al 2007). Available evidence does not support consistent effects Vascular Health and Risk Management 2008:4(6) 1222
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of DPP-4 inhibitors on insulin sensitivity (Pratley et al 2006; 
Raz et al 2006; Rosenstock et al 2006; Garber et al 2007, 
2008; Hanefeld et al 2007; Azuma et al 2008; Utzschneider 
et al 2008). On the other hand, improving insulin sensitivity 
is the main mechanism whereby thiazolidinediones (TZDs) 
lower plasma glucose (Yki-Jarvinen 2004). Therefore, due 
to the marked differences in mechanisms of actions between 
DPP-4 inhibitors and TZDs, it was plausible to evaluate the 
therapeutic potential of the combination between the 2 drug 
classes. This article will focus on the two DPP-4 inhibitors 
sitagliptin (Januvia®, Merck and Co., Inc.) and vildagliptin 
(Galvus®, Novartis) as part of combination therapy with the 
TZD pioglitazone for treatment of type 2 diabetes. Sitagliptin 
received Federal Drug Administration (FDA) approval in 
October 2006. Vildagliptin has not yet been approved in the 
USA, but the drug is used in Mexico and Brazil. Combination 
therapy formed of DPP-4 inhibitors and metformin has been 
reviewed in a recent issue of this journal (Ahren 2008).
Clinical trials of DPP-4 inhibitors 
plus pioglitazone
The combination of pioglitazone and DPP-4 inhibitors in 
type 2 diabetes was evaluated in 3 trials of 24-week duration 
each. Two of the three trials evaluated the addition of 
sitagliptin or vildagliptin to ongoing pioglitazone therapy 
(Rosenstock et al 2006; Garber et al 2007), whereas the third 
trial evaluated the concomitant initiation of both vildagliptin 
and pioglitazone in drug-naïve patients (Rosenstock et al 
2007). An overview and the main results of those studies 
are summarized in Table 1. No trials have been published 
on the combination between DPP-4 inhibitors and the 
second TZD rosiglitazone. Although no head-to-head trials 
have compared sitagliptin with vildagliptin, available data 
suggest that the two drugs have similar efﬁ  cacy and safety 
proﬁ  le (Mikhail 2008). Sitagliptin is given as 100-mg tablet 
po qd regardless of meal intake. Vildagliptin can be given 
as 50 mg bid or 100 mg qd, with no signiﬁ  cant difference 
in efﬁ  cacy between the two dosing regimens (Pi-Sunyer 
et al 2007). The smaller dose of vildagliptin 50 mg qd is 
infrequently used and appears less effective than the 100-mg 
dose (Pi-Sunyer et al 2007).
Efﬁ  cacy parameters
Effects on hemoglobin A1c 
(HbA1c) levels
In patients with type 2 diabetes receiving pioglitazone 
30 to 45 mg qd (mean baseline HbA1c 8%), the addition 
of sitagliptin (100 mg qd) was associated with a mean 
reduction in HbA1c values of 0.8% and 0.7% after 
24 weeks compared with baseline and placebo, respectively 
(Rosenstock et al 2006). Similar results were obtained with 
the addition of vildagliptin to patients with type 2 diabetes 
inadequately controlled (average baseline HbA1c 8.7%) 
on maximal pioglitazone doses (45 mg/day). Thus, the 
mean reductions in HbA1c values with vildagliptin 
50 mg bid were 1.0% and 0.7% compared with baseline 
and placebo, respectively (Garber et al 2007). In a third 
trial, drug-naïve patients with inadequate glycemic con-
trol (mean baseline HbA1c ∼8.7%) were randomized to 
4 groups to receive pioglitazone 30 mg qd, vildagliptin 
50 mg qd plus pioglitazone 15 mg, vildagliptin 100 mg 
plus pioglitazone 30 mg qd, and vildagliptin 100 mg qd 
(Rosenstock et al 2007). After 24 weeks, mean reductions 
in HbA1c from baseline were 1.4% with pioglitazone 
monotherapy, 1.7% with 50/15 mg combination, 1.9% 
with 100/30 mg combination, and 1.1% with vildagliptin 
monotherapy (Garber et al 2007). Thus, the effect of the 
previous drug combination on HbA1c levels was less than 
additive, ie, the combination of pioglitazone 30 mg qd plus 
vildagliptin 100 mg qd resulted in HbA1c reduction of 
1.9%, which was smaller in magnitude than the sum of the 
HbA1c reduction achieved by pioglitazone monotherapy 
(1.4%) plus vildagliptin monotherapy (1.1%). The combi-
nation of metformin plus sitagliptin appears to have similar 
efﬁ  cacy, 1.9% with sitagliptin 50 mg bid + metformin 
1,000 mg bid, 0.7% with sitagliptin 100 mg qd, and 1.1% 
with metformin 1000 mg bid (Goldstein et al 2007). 
Importantly, the time course of change in HbA1c values 
after initiation of therapy showed maximal reductions at 
16 to 18 weeks followed by a plateau (Rosenstock et al 
2006, 2007; Garber et 2007). The proportions of patients 
who achieved the target HbA1c levels 7% at the end of 
trials increased with the combination of pioglitazone plus 
sitagliptin 100 mg qd or vildagliptin 50 mg bid to 36% to 
65% versus 15% to 43% with pioglitazone monotherapy 
(Rosenstock et al 2006, 2007; Garber et 2007).
Effects on fasting plasma glucose
Two studies have shown signiﬁ  cantly greater reduction 
in levels of fasting plasma glucose of ∼17 mg/dL with the 
addition of sitagliptin 100 mg qd (Rosenstock et al 2006) or 
vildagliptin 50 mg bid (Rosenstock et al 2007) to pioglitazone 
30 to 45 mg/day compared with pioglitazone monotherapy. 
However, in the third trial, the difference in fasting plasma 
glucose levels between patients receiving vildagliptin Vascular Health and Risk Management 2008:4(6) 1223
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50 mg bid plus pioglitazone 45 mg qd and those receiving 
placebo plus pioglitazone was ∼10 mg/dL, and did not reach 
statistical signiﬁ  cance (Garber et al 2007).
Effects on postprandial plasma glucose
Based on their incretin effects, DPP-4 inhibitors act 
mainly by lowering blood glucose levels after meals. In 
the two trials that evaluated this glycemic parameter, the 
decrease in postprandial plasma glucose (PPG) values 
after a standard meal test was signiﬁ  cantly greater with 
the vildaglitin-pioglitazone combination compared with 
pioglitazone-placebo combination (Garber et al 2007; 
Rosenstock et al 2007). However, the difference in PPG 
levels between the two groups was somewhat lesser than 
that expected, averaging 34 to 36 mg/dL with the high dose 
of vildagliptin (100 mg/day) (Garber et al 2007; Rosenstock 
et al 2007). Indeed, the corresponding reduction in PPG 
was greater (∼47 mg/dL) in trials using DPP-4 inhibitors 
as monotherapy despite similar baseline PPG values 
(∼250–260 mg/dL) (Aschner et al 2006; Raz et al 2006). 
The explanation of this discrepancy is unclear, but could 
be related to differences in patients’ characteristics and 
protocol of the meal tolerance test used. In addition, only 
a subset of patients, that might not be representative of 
the whole study group, was selected to undergo the meal 
tolerance test.
Table 1 Overview of trials of combination of DPP-4 inhibitors with pioglitazone
Clinical trial Rosenstock et al 2006 Garber et al 2007 Rosenstock et al 2007
Mean age (years) 56 54 52
Patient number 
at randomization
353 463 607
Approximate gender 
proportions (%) 
men/women
55/45 50/50 60/40
Caucasian or white 
race
72% 81% 40%a
Mean body mass 
index (kg/m2)
31.5 32.5 29a
Mean duration of 
diagnosed diabetes 
(years)
6.1 4.6 2
Drug treatment 
before randomization
Pioglitazone 30–45 qd Pioglitazone 45 mg qd Drug-naïve
Baseline mean HbA1c 8% 8.7% 8.7%
Design Randomized, double-
blind, placebo-controlled
Randomized, double-blind, placebo-controlled Randomized, double-blind, double-dummy
Patient groups 2 groups: sitagliptin 
100 mg qd + pioglitazone 
30–45 mg qd (n = 175) 
and sitagliptin 100 mg 
qd + placebo (n = 178)
3 groups: vildagliptin 50 mg qd + pioglitazone 
45 mg qd (n = 147), vildagliptin 50 mg 
bid + pioglitazone 45 mg qd (n = 158), and 
placebo + pioglitazone 45 mg qd (n = 158)
4 groups: pioglitazone 30 mg 
qd (n = 161), vildagliptin 100 mg qd + 
pioglitazone 30 mg qd (n = 148), vilda-
gliptin 50 mg qd + pioglitazone 15 mg qd 
(n = 144), vildagliptin 100 mg (n = 153)
Follow-up 24 weeks 24 weeks 24 weeks
Completion rates in 
various groups
85%–89% 78%–84% 80%–88%
Mean HbA1c reduc-
tion in sitagliptin
or vildagliptin groups
0.7% with sitagliptin vs 
placebo
0.5% with vildagliptin 50 mg vs placebo, and 
0.7% with vildagliptin 50 mg bid vs placebo
1.4% with pioglitazone 30 mg qd, 1.9% 
with vildagliptin 100 mg qd+ pioglitazone 
30 mg qd, 1.7% with vildagliptin 50 mg 
qd + pioglitazone 15 mg qd, and 1.1% 
with vildagliptin 100 mg vs baseline
Proportions of patients 
with HbA1c 7% at 
the end of trials
23% with placebo vs 45% 
with sitagliptin
15% with placebo, 29% with vildagliptin 
50 mg qd, 36% with vildagliptin 50 bid
43% with pioglitazone 30 mg qd, 43% 
with vildagliptin 100 mg qd, 52% with 
50/15 combination, 65% with 100/50 
combination
aIn this trial, 45% of patients were Asian, which may explain the relatively low body mass index.Vascular Health and Risk Management 2008:4(6) 1224
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Safety of the combination of DPP-4 
inhibitors and pioglitazone
Effect on hypoglycemia
Consistent with the glucose-dependent insulinotropic effect 
of incretin-based therapy (Mikhail 2006), the addition of 
sitagliptin or vildagliptin to pioglitazone did not result in a 
signiﬁ  cant increase in the incidence or severity of hypoglyce-
mia. Overall, the incidence of hypoglycemia was uncommon 
(2%), and none of the episodes was severe (Rosenstock 
et al 2006, 2007; Garber et al 2007).
Effect on weight
Weight gain is the most common adverse effect of drugs 
pertaining to the TZD class. In a large-scale randomized trial, 
the use of pioglitazone was associated with an average weight 
gain of 4 kg compared with placebo after a mean follow-up 
of 34.5 months (Dormandy et al 2005). On the other hand, 
DPP-4 inhibitors have generally neutral effect on weight 
(Mikhail 2008). Thus, the addition of sitagliptin 100 mg 
qd to pioglitazone 30–45 mg qd did not result in signiﬁ  -
cant weight gain compared with the addition of placebo to 
pioglitazone, the average weight gain after 24 weeks being 
1.8 and 1.5 kg in the combination group and pioglitazone 
monotherapy group, respectively (Rosenstock et al 2006). 
Yet, the combination of vildagliptin 100 mg/day plus pio-
glitazone 45 mg qd was associated with greater weight gain 
(2.7 kg) compared with pioglitazone monotherapy (1.4 kg), 
(p = 0.03) (Garber et al 2007). Likewise, the high-dose com-
bination pioglitazone 30 mg qd/vildagliptin 100 mg qd was 
associated with a trend toward more weight gain (2.1 kg) 
compared with pioglitazone monotherapy 30 mg qd (1.4 kg) 
(Rosenstock et al 2007). Taken together, the addition of 
DPP-4 inhibitors to pioglitazone may have either negligible 
effect or may slightly exacerbate the weight gain induced 
by pioglitazone.
Effects on edema
Peripheral edema is another common adverse effect of 
TZDs. In one trial, peripheral edema occurred more fre-
quently in patients randomized to vildagliptin plus piogli-
tazone 45 mg qd than to placebo plus pioglitazone 45 mg 
qd (Garber et al 2007). Thus, edema was reported by 8.2%, 
7%, and 2.5% of patients receiving vildagliptin 50 mg qd, 
vildagliptin 50 mg bid, and placebo, respectively. However, 
the excess incidence in edema was not observed in 2 other 
trials using vildagliptin or sitagliptin in addition to piogli-
tazone (Rosenstock et al 2006, 2007). The reasons for this 
discrepancy are unclear, but may be related in part to the 
pioglitazone doses. Indeed, the low-dose combination of 
pioglitazone 15 mg plus vildagliptin 50 mg qd was associated 
with low incidence of edema (3.5%) and also of weight gain 
(1.4 kg) compared with the high-dose combination formed 
of pioglitazone 30 mg plus vildagliptin 50 mg bid which 
was associated with higher incidence of edema (9.3%) and 
weight gain (2.1 kg) (Rosenstock et al 2007). Interestingly, 
the use of low-dose combination formed of pioglitazone 
15 mg/vildagliptin 50 mg led to a mean in HbA1c levels 
of 1.7%, a reduction not signiﬁ  cantly different from the 
reduction associated with the high-dose combination (1.9%) 
(Rosenstock et al 2007). Therefore, the low-dose combina-
tion may be a more appropriate option if edema or weight 
gain becomes a concern.
Effects on plasma lipids
Pioglitazone in maximum doses (45 mg qd) has been shown 
to raise plasma levels of high-density lipoprotein-cholesterol 
(HDL-C) and low-density lipoprotein cholesterol (LDL-C) 
by up to 15%, and lowers triglycerides by ∼12% compared 
with baseline values after 24 weeks (Goldberg et al 2005). 
Conversely, studies of DPP-4 inhibitors overall did not show 
signiﬁ  cant effects on plasma lipoproteins (Mikhail and Cope 
2007). When sitagliptin or vildagliptin was added to ongoing 
pioglitazone therapy, no significant changes in plasma 
lipids occurred (Garber et al 2007; Rosenstock et al 2007). 
Meanwhile, when used as initial therapy in treatment-naïve 
patients, the high-dose combination formed of vildagliptin 
50 mg bid and pioglitazone 30 mg was associated with sig-
niﬁ  cantly lower LDL-C (by 10%) and non-HDL-C (by ∼7%) 
compared with pioglitazone monotherapy (Rosenstock 
et al 2007). Levels of triglycerides and HDL-C were not 
signiﬁ  cantly different between the two groups (Rosenstock 
et al 2007). Taken together, the addition of DPP-4 inhibitors 
to pioglitazone either has no effect or may improve some 
lipid parameters such as LDL-C levels.
Effect on insulin sensitivity
No signiﬁ  cant effect was found on insulin sensitivity when 
sitagliptin or vildagliptin was added to ongoing pioglitazone 
therapy (Garber et al 2007; Rosenstock et al 2006). In fact, 
most (Pratley et al 2006; Raz et al 2006; Hanefeld et al 
2007; Garber et al 2008), but not all (Azuma et al 2008; 
Utzschneider et al 2008) studies have shown that DPP-4 
inhibitors did not enhance insulin sensitivity. Methods 
of measurements of insulin resistance may be one factor 
explaining discrepant results. Nevertheless, on balance, the Vascular Health and Risk Management 2008:4(6) 1225
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strength of data suggests that DPP-4 inhibitors have no major 
impact on insulin resistance.
Other adverse effects
In general, the addition of sitagliptin or vildagliptin to 
pioglitazone was well tolerated without serious adverse 
effects. However, discontinuation rates due to adverse effects 
were slightly higher with combination therapy compared 
with the pioglitazone monotherapy. The highest difference in 
discontinuation rates was reported between the combination 
of sitagliptin 100 mg qd plus pioglitazone 30 to 45 mg qd 
versus placebo plus pioglitazone 30 to 45 mg qd, 6% and 
1%, respectively (p  0.05). Unfortunately, the authors 
did not specify the type of adverse effects that led to drug 
discontinuation (Rosenstock et al 2006).
Clinical implications
The combination of DPP-4 inhibitors and pioglitazone 
provides several advantages. First, because of their distinct 
mechanism of action, DPP-4 inhibitors combined with 
pioglitazone lower HbA1c with approximately the same 
magnitude observed in trials of DPP-4 inhibitors used as 
monotherapy, ie, ∼0.7% mean reduction versus baseline 
after 24 weeks in patients with average HbA1c of ∼8.5% at 
study entry (Aschner et al 2006; Raz et al 2006). Second, 
the DPP-4 inhibitors/pioglitazone combination is generally 
well tolerated. Third, the addition of DPP-4 inhibitors to 
pioglitazone does not increase the frequency or the severity 
of hypoglycemia (Rosenstock et al 2006, 2007; Garber 
et al 2007). Fourth, the administration of the combination 
is simple, and both drugs can be taken orally once daily 
irrespective of meal intake. Furthermore, sitagliptin and 
pioglitazone can be used in renal insufﬁ  ciency (see below).
Meanwhile, current DPP-4 inhibitors have important 
limitations. First, in terms of efﬁ  cacy, the addition of a DPP-4 
inhibitor to pioglitazone raised the proportions of patients 
who achieved the goal of HbA1c value below 7% from 15% 
to 43% with pioglitazone monotherapy to 36% to 65%, ie, the 
drug combination allowed ∼20% more patients to attain opti-
mum glycemic control, a fact that underscores its moderate 
efﬁ  cacy and the difﬁ  culty of optimizing diabetes control in 
general. Second, data regarding the efﬁ  cacy and safety of the 
DPP-4 inhibitor/pioglitazone combination beyond 24 weeks 
are lacking. Vildagliptin in combination with metformin was 
evaluated in studies lasting one year (Ahren et al 2004) and 
as monotherapy for up to 2 years (Goke et al 2008), whereas 
sitagliptin was evaluated as monotherapy for up to 1 year 
(Nauck et al 2007). Third, the cost of the combination of 
pioglitazone/DPP-4 inhibitor is higher than the commonly 
used combination formed of metformin and a sulfonylurea, 
but the exact difference in cost is unclear at present. Fourth, 
although all the trials that evaluated the combination were 
double-blinded and generally of good quality, they were 
sponsored by the corresponding manufacturer, and there-
fore may be open to different bias. Moreover, those trials 
excluded patients with different co-morbidities; therefore the 
results may not be applicable to sicker patients encountered 
in clinical practice.
In view of the above limitations, metformin will remain 
the oral drug of choice for initial treatment of type 2 diabe-
tes due to multiple advantages such as reassuring long-term 
safety, acceptable efﬁ  cacy, induction of mild weight loss, 
low propensity for causing hypoglycemia, and low-cost 
(Nathan et al 2006; Bolen et al 2007). If glycemic control 
is not achieved with metformin alone, one or more of the 
following agents can be added: a sulfonylurea, a TZD, a 
DPP-4 inhibitor, exenatide, or insulin depending on the 
extent of metabolic deterioration, patient’s preference, 
and local resources. For example, in an obese patient 
concerned about further weight gain or hypoglycemia, the 
combination of metformin plus a DPP-4 inhibitor seems 
appropriate.
Meanwhile, the combination of DPP-4 inhibitors and 
pioglitazone can be particularly useful in the following 
situations:
1. Patients who do not tolerate metformin or a sulfonylurea 
due to adverse effects (eg, diarrhea with metformin and 
hypoglycemia with a sulfonylurea).
2. Patients with renal insufﬁ  ciency in whom metformin is 
contraindicated. Currently, sitagliptin is the only DPP-4 
inhibitor that may be used in various degrees of renal 
impairment including patients on hemodialysis (see 
Table 2 for dosage adjustment in renal insufﬁ  ciency) 
(Januvia® package insert 2007; Chan et al 2008). Mean-
while, safety data regarding the use of vildagliptin in 
renal insufﬁ  ciency are not yet available. With respect to 
pioglitazone, pharmacokinetic studies suggest that the 
drug may be safely used in maximum doses (45 mg qd) 
in renal failure (Budde et al 2003). However, caution 
should be exercised in the latter situation, as renal failure 
appears to increase the risk of heart failure and pulmonary 
edema in TZD-treated patients (Kermani and Garg 2003; 
Manley and Allock 2003).
The advantages and limitations of the combination 
of DPP-4 inhibitors with pioglitazone are summarized in 
Table 2.Vascular Health and Risk Management 2008:4(6) 1226
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Future directions
Long-term randomized trials are needed to examine the safety 
of the combination of pioglitazone and DPP-4 inhibitors, its 
effects on hard endpoints such as cardiovascular morbidity and 
mortality, and its impact on the course of diabetes and β-cell 
function. Moreover, direct comparison with other drug combi-
nations is required to help determine the safest and most effec-
tive approach of combination therapy in type 2 diabetes.
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